Gemcitabine Hydrochloride for the Treatment of SARS-CoV-2

With high antiviral potency and favorable pharmacokinetics parameters, nucleoside analogs are the largest class of small molecule-based antivirals for chemotherapy of virus infections. Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs is confident in tailoring gemcitabine hydrochloride validation service for the treatment of SARS-CoV-2 to meet our clients’ demands precisely.

Introduction of Gemcitabine Hydrochloride

Gemcitabine hydrochloride is a 2'-deoxycytidine hydrochloriode having geminal fluoro substituents in the 2'-position. It is a deoxycytidine analog that inhibits DNA synthesis and repair and it can inhibit the growth of several cell lines, such as BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells. As an inhibitor of ribonucleotide reductase, this compound has been used in the treatment of various carcinomas, including non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. Studies have shown that gemcitabine hydrochloride can be used in the prophylaxis or therapy of virus diseases.

Repurposing of Gemcitabine Hydrochloride Against Coronavirus Infection

In order to prevent the emergence of a novel virus from growing into a pandemic human pathogen, it is critical that public health clinicians can diagnose the infection, control its spread and treat those afflicted. First and foremost, we need more countermeasures that can be used at the early phase to provide an immediate treatment response while more appropriate therapies are being developed. Given the time and costs of novel therapeutics, one feasible and rapid response is through repurposing of existing clinically developed products, with known safety profiles, availability and lower cost. In view of this, a subset of drugs has been screened against SARS-CoV and MERS-CoV to identify drugs with broad activity against coronaviruses in preparedness for potential future emerging coronaviruses. The effect of gemcitabine hydrochloride on MERS-CoV or SARS-CoV has been investigated. It has been demonstrated that gemcitabine hydrochloride inhibits both MERS-CoV and SARS-CoV with micromolar EC₅₀ and low toxicity.

Fig.1 Antiviral activity of gemcitabine hydrochloride and toremifene citrate. (Dyall, 2014)

Gemcitabine Hydrochloride for the Treatment of SARS-CoV-2

Experienced in antiviral drug discovery, Creative Biolabs compiles a list of drugs potential to be used in the treatment of SARS-CoV-2 infection based on experience in treating a series of viral diseases, such as MERS-CoV and SARS-CoV infection. We have demonstrated that libraries of approved compounds can be used to screen inhibitors of viruses. Gemcitabine hydrochloride is one of nucleoside analogue inhibitors for this purpose. We are proud to introduce our professional service in the validation of gemcitabine hydrochloride for the treatment of SARS-CoV-2.

The emergence of SARS-CoV-2 has revealed the seriousness of coronaviruses as potential emerging human pathogens and highlighted the necessity and value to facilitate rapid responses to infectious diseases. With extensive experience in antiviral drug discovery, Creative Biolabs offers high-quality validation service of gemcitabine hydrochloride for the treatment of SARS-CoV-2. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Dyall, J.; et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial agents and chemotherapy. 2014, 58(8):4885-93.

For Research Use Only. We do not provide direct services or products for patients.